New silica-based chromatography media helps biopharmaceutical manufacturers achieve demanding purity targets while supporting ...

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 ...

These honors underscore Cepheid's continued focus on helping healthcare providers deliver A Better Way through timely ...

Granata Bio Corporation, a biopharmaceutical company dedicated to advancing reproductive medicine, today announced the ...

Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced the appointment of Chadi ...

Antogen, Inc., a biotechnology company pioneering next-generation personalized diagnostics through immunopeptidomics, today ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of ...

New data from six landmark trials reinforce practice-changing results of Enhertu and Datroway across a broad spectrum of ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company ...

Seasoned legal and compliance executive brings global product launch, strategic transaction and international operational ...

Two strong partners aim to accelerate AI-enabled clinical development Building a foundation for Digital Patient Twins to ...